Phil Rivers raises $30M Series A as China's AI biotechs draw fresh capital
What's the deal? Phil Rivers Technology, a Chinese AI-driven drug developer, has raised $30 million in a Series A round backed by venture capital and private equity firms. The company announced the financing on 5 August 2026, joining peer Beyang TherapeuticsDealroom has a profile for this one. Try Dealroom →, which raised a comparable sum in its own round.
What does it do? Phil Rivers runs an AI-powered platform that aims to speed pharmaceutical innovation through computational medicine and data-driven drug discovery.
Why it stands out: The round ranks in the 91st percentile by size among Series A deals in China's health sector over the trailing 48 months, based on a sample of 398 rounds. That places Phil Rivers well ahead of the typical early-stage biotech raise in the region.
Why now? The financing lands more than six months after an earlier wave of Chinese AI-driven drug developers won backing from venture capital and private equity firms. A second cohort of peers is now returning to the fundraising scene.
The signal: Investor appetite for AI-led drug discovery in China shows no sign of cooling. Repeat rounds across the sector point to a maturing market where computational medicine startups are becoming a fixture of the country's biotech financing landscape.
Read more: Scrip
Image credit: U.S. Department of Energy
